Suggestions
Sadik Kassim
Experienced Chief Technology Officer in Genomic Medicines
Sadik Kassim serves as the Chief Scientific Officer and Chief Technology Officer (Genomic Medicines) at Danaher Corporation, a role he has held since December 2021. In this capacity, he is responsible for developing platform R&D strategies for genomic medicines and overseeing their implementation across various Danaher operating companies. He also leads scientific and technical diligence efforts related to external R&D collaborations, venture investments, and mergers and acquisitions in the genomic medicine space.1
Education and Background
Kassim completed his PhD in viral immunology, focusing on the innate immune response to herpes simplex virus type 1 and influenza virus. His academic background provides a strong foundation for his work in biotechnology and genomic medicine.1
Previous Experience
Before joining Danaher, Kassim held several significant positions:
- Chief Technology Officer at Vor Biopharma (October 2019 - December 2021): He led technical operations for the manufacture of CRISPR gene-edited hematopoietic stem cells and CAR-T cell therapies.
- Executive Director of Process Design at Kite Pharma (January 2019 - September 2019): He managed a team responsible for designing manufacturing processes for CAR and TCR-based therapies.
- Chief Scientific Officer at Mustang Bio (March 2018 - January 2019): He developed high-throughput analytical assays for gene-modified T cell therapy products aimed at cancer immunotherapy.1
Current Roles
In addition to his role at Danaher, Kassim also serves as an advisor to RA Capital Management, where he provides insights on opportunities in cell and gene therapy.1
